| Today’s Big NewsMar 27, 2025 |
|
Thursday, April 3, 2025 | 11am ET / 8am PT Join us for an insightful webinar on the latest advancements in cell and gene therapy, focusing on the innovative Cas9-CLIPT (Cleaved, Linearized with Protein Template) technology. Learn more about this groundbreaking technology designed to improve the efficiency of genome editing. Register now. 
|
|
| By Gabrielle Masson The federal government is cutting 3,500 full-time FDA employees and 1,200 NIH workers as part of an overarching move designed to eliminate 10,000 jobs in the Department of Health and Human Services. |
|
|
|
By James Waldron Tara Schwetz, Ph.D., a deputy director at the National Institutes of Health and overseer of ARPA-H's creation, has reportedly been put on administrative leave in the latest shake-up to the health agency’s leadership. |
By James Waldron Nkarta is laying off a third of its employees, including half of the biotech’s executive leadership, as the company diverts cash to its lead CAR NK candidate. |
By James Waldron Arbutus Biopharma is stripping its workforce back to just a “core team” needed to oversee mid-stage trials of the biotech's potential functional cure for hepatitis B. |
By Gabrielle Masson Cell- and gene-therapy-focused ElevateBio has let go of 17% of staffers as part of the company’s second layoff round since raising $401 million nearly two years ago. |
By Darren Incorvaia Lyndra Therapeutics, which spun out of Moderna co-founder Robert Langer’s lab at the Massachusetts Institute of Technology in 2015, is winding down operations this week, a person with knowledge of the situation told Fierce Biotech. |
By James Waldron Eye care giant Alcon appears to have gained the upper hand in the ongoing power struggle with Aurion Biotech by securing a majority stake in the clinical-stage biotech and replacing its CEO. |
By Nick Paul Taylor Equillium’s phase 3 graft-versus-host disease trial has missed its primary endpoint and two key secondary objectives. But the biotech brushed off the setback, highlighting other secondary endpoints and post hoc analyses to make the case it could file for FDA approval next year. |
By Nick Paul Taylor Candel Therapeutics has identified a subpopulation of lung cancer patients living longest on its oncolytic virus, leading the biotech to narrow its focus as it heads towards a potentially registrational trial. |
By Conor Hale According to the FDA’s public database, since the start of this year the agency has issued only two de novo clearances, far below its quarterly average. |
By Noah Tong The administration will also consolidate offices and create a new Administration for a Healthy America. |
By Darren Incorvaia Cardio-focused company Kardigan is sewing a new digital data platform into its R&D patchwork through the acquisition of heart health tech firm Prolaio. |
By Angus Liu Merck & Co.’s subcutaneous formulation of Keytruda has matched up to the original intravenous version on two blood concentration measurements, paving way for a potential FDA approval that could give patients a more convenient option of the widely used cancer drug. |
Fierce podcasts Don’t miss an episode |
| Pair Team supports community-based organizations via California's Medi-Cal Community Care Hubs model. |
|
|---|
|
|
|
Tuesday, April 8, 2025 | 1pm ET / 10am PT Learn how AI-powered digital phenotyping and real-world data (RWD) help identify overlooked patient populations, bridge gaps between clinical guidelines and real-world treatment, and refine commercial strategies. Join experts to discover how AI-driven insights can optimize market positioning and ensure therapies reach the right patients. Register now! 
|
|
Whitepaper Read about four trends that will shape the innovations, therapies, & market landscape in oncology during 2025 & beyond. Presented by Blue Matter, strategic consultants in the life sciences |
Whitepaper Discover how to revolutionize your vaccine trials with Avacare's latest white paper. Gain exclusive access to innovative, data-driven recruitment strategies that ensure diverse, efficient, and high-quality vaccine trials. Sponsored by: Avacare Clinical Research Network |
Whitepaper Develop your CAR molecule faster Sponsored by: Cell Signaling Technology |
| Accepting Nominations Now |
|
| Accepting Nominations Now |
|
|
| |
|
